newsfilter
← Latest News
PR Newswire·

Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements